sur Mainz BioMed N.V.
Mainz Biomed and CARE Partner for Enhanced Cancer Screening
Mainz Biomed N.V., a leader in cancer diagnostics, has announced a strategic partnership with CARE diagnostica Laborreagenzien GmbH. This collaboration aims to enhance colorectal cancer screening services for health insurance companies in Germany.
CARE currently collaborates with 19 health insurance companies, offering online-based screening using fecal immunochemical tests (FIT). The new partnership will broaden services to include Mainz Biomed's ColoAlert®, which utilizes molecular genetic analysis for early cancer detection.
This agreement, effective immediately, aligns with the increasing demand for personalized and early intervention diagnostic solutions. It further consolidates Mainz Biomed's presence in the German market, expanding distribution of ColoAlert® and meeting rising consumer needs.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Mainz BioMed N.V.